Keeping Pace in Women’s Cancer: Focus on Endometrial Carcinoma

Keeping Pace in Women’s Cancer: Focus on Endometrial Carcinoma

Keeping Pace in Women’s Cancer: Focus on Endometrial Carcinoma

Explore the changing landscape and new treatment options for recurrent/metastatic endometrial cancer with special attention to microsatellite tumors.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    There remains a critical unmet need for effective therapies following the recurrence of endometrial cancer. In this activity, Drs. Linda Duska and Richard Penson assess the role of immunotherapy and targeted therapies in managing advanced endometrial cancers, as well as the importance of evaluating the microsatellite and mismatch repair biomarker status of recurrent and metastatic endometrial cancer.

    Since the release of this activity, the FDA has approved the use of dostarlimab for the treatment of patients with recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing chemotherapy and whose cancers have a specific genetic feature known as dMMR, as determined by an FDA-approved test. Visit the FDA statement dated 22 April 2021 to learn more.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Richard T. Penson MD, MRCP 
    Clinical Director Medical Gyn-Oncology
    Massachusetts General Hospital
    Boston, MA

    Royalty:  BMJ Publishing, Elsevier Ltd., UptoDate, Wolters Kluwer Health
    Consulting Fees: AbbVie, AstraZeneca, Care4ward (Unpaid), Clovis Oncology, Curio Science, Eisai Inc., Genentech, Janssen Oncology (J&J), Merck & Co., Mersana Therapeutics, Inc., NewLink Genetics, Nexus Global Group, Pieris Pharma Inc, Roche, Inc., Sutro Biopharma, Syndax Pharmaceuticals, Tesaro Inc., Vascular Biogenics Ltd.
    Contracted Research: Array BioPharma Inc., AstraZeneca., Eisai Inc., Genentech, Inc., Regeneron, Sanofi-Aventis US LLC, Tesaro Inc., Vascular Biogenics Ltd (all through intuition) 

    Linda R Duska, MD, MPH
    Professor, Gynecology Oncology
    University of Virginia School of Medicine
    Charlottesville, VA

    Contracted Research/Clinical Trials (Grants): AbbVie, Aduro, Advaxis, BioTech, Cerulean/NextGen, Eisai, Genentech/Roche, GlaxoSmithKline/Novartis, Inovio, LEAP Therapeutics, Ludwig, Lycera, Merck, Morab, MorphoTek, Pfizer, Syndax, Tesaro
    Consulting Fees: Advance Medical, Astra Zeneca, Cue Biopharma, Genentech/Roche, Inovio, Merck, MorphoTek, Parexel

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Nick Lombardi has disclosed ownership Interest in Vertex Pharmaceuticals.
    • Brian P. McDonough, MD, FAAFP has nothing to disclose.
    • Tricia O’Leary has nothing to disclose.
    • Colleen Resnick has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Recognize challenges in the treatment of recurrent/metastatic endometrial cancer, and recent efforts to overcome these challenges
    • Evaluate clinical evidence on promising immunotherapy approaches either as monotherapy or in combination with other agents to address unmet needs in recurrent/metastatic endometrial cancer
    • Discuss testing strategies to classify endometrial cancer and identify patients that will benefit from approved and emerging immunotherapy approaches based on biomarkers, safety profiles, and efficacy data
  • Target Audience

    This activity is designed to meet the educational needs of gynecologic oncologists. medical oncologists, pathologists, gynecologists, and oncology NPs/PAs.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by independent educational grants from Eisai, GlaxoSmithKline, and Merck.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free